

UNCLASSIFIED

AD NUMBER
ADB283918
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 2002. Other requests shall be referred to US Army Medical Research and Materiel Comd., 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9266

TITLE: DNA Vaccination Against Metastatic Breast Cancer

PRINCIPAL INVESTIGATOR: Lawrence B. Lachman, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas
M. D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: July 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20021114 193

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9266

Organization: The University of Texas M. D. Anderson Cancer Center

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2002		3. REPORT TYPE AND DATES COVERED Final (1 Jul 99 - 30 Jun 02)	
4. TITLE AND SUBTITLE DNA Vaccination Against Metastatic Breast Cancer				5. FUNDING NUMBERS DAMD17-99-1-9266	
6. AUTHOR(S) Lawrence B. Lachman, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M. D. Anderson Cancer Center Houston, Texas 77030 E-Mail: lachman@odin.mdacc.tmc.edu				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.					12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) HER2/neu over-expression is found in 30-40% of breast cancer biopsy and is indicative of metastasis and poor prognosis. A DNA vaccine targeting HER2/neu could have significant therapeutic and preventative application by controlling the growth and spread of highly aggressive HER2/neu ⁺ cells. Although DNA vaccines have shown effectiveness in clinical trials, it is essential to demonstrate pre-clinical effectiveness for anti-tumor DNA vaccines before clinical testing can begin. We have shown that vaccination of mice with a novel plasmid expressing the DNA sequence for HER2/neu protected mice from tumor incidence when challenged with a HER2/neu ⁺ murine breast tumor cell line injected directly into mammary tissue or injected intravenously. In the previous year we switched to an improved version of our DNA vaccine and the results have been even better. We have also confirmed that vaccination can reduce tumor incidence and prolong survival in mice containing neu as a transgene under the control of a breast-specific promoter, demonstrating that our vaccine works with both naturally occurring and transplanted neu ⁺ breast tumors. We have concluded our work to determine if vaccination following surgical-removal of the initial tumor will prolong survival. Unfortunately, our vaccine is not powerful enough to be used after a tumor has been established—even if the tumor is removed by surgery before vaccination.					
14. SUBJECT TERMS breast cancer, DNA vaccines, HER2/neu, tumor antigens, immunity				15. NUMBER OF PAGES 20	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	8
References.....	8
Appendices.....	9-19

INTRODUCTION:

HER2/*neu* over-expression is found in 30-40% of breast cancer biopsy and is indicative of metastasis and poor prognosis (1). Although significant advances have been made in the treatment of breast cancer, once metastasis has occurred the possibility of a complete cure is unlikely (1). A vaccine targeting HER2/*neu* could have significant therapeutic and preventative application by controlling the growth and spread of highly aggressive HER2/*neu*⁺ cells (2). The newest type of tumor vaccines, gene vaccines, encode the DNA sequence for tumor antigens. Bacterial expression plasmids containing tumor gene sequences have been shown to induce strong anti-tumor immunity in mice (3). Although gene vaccines have shown effectiveness in clinical trials for infectious diseases (4), it is essential to demonstrate pre-clinical effectiveness for anti-tumor vaccines before clinical testing can begin (5-7). We have shown that vaccination of mice with a novel plasmid expressing the DNA sequence for HER2/*neu* protected mice from tumor incidence when challenged with a HER2/*neu*⁺ murine breast tumor cell line injected directly into mammary tissue. We also found that vaccination was able to reduce metastasis when the tumor was injected intravenously, a model of tumor metastasis. The plasmid we used for vaccination, called ELVIS, was created by Chiron Corp. (Emeryville, CA) and incorporates unique properties of Sindbis virus, a non-pathogenic alphavirus (8). Recently, Chiron Corp. has provided us with a more advanced version of their plasmid called ELVIS2, and we have shown it to be even more powerful than the original ELVIS when injected before mice a challenged with a tumor (protective vaccination). However, ELVIS2-*neu* was not able to prolong the life of mice when vaccinated followed surgical removal of a primary *neu*⁺ breast tumor (surgery model) or when vaccination was performed on a tumor bearing mouse (race model). Thus, different strategies are required in our two therapeutic vaccination models (surgery and race). The first strategy we are testing is to increase the effectiveness of the vaccine is to combine vaccination and chemotherapy. Several publications have indicated that combined chemotherapy and vaccine therapy is superior to either treatment used alone (9,10).


BODY:

The enclosed reprint "DNA Vaccination Against *neu* Reduces Breast Cancer Incidence and Metastasis in Mice" (11) contains a complete description of our accomplishments related to Task 1 of the Statement of Work. Below is shown the bulleted points from the Statement of Work for Task 1 with corresponding reference to the figure and page number of our article in which the research is described.

Task 1: To demonstrate that mice vaccinated with ELVIS-*neu* are protected from the growth and metastasis of mammary tumor cells expressing HER2/*neu* (**protective vaccination**). (months 1-24)

- Immunize mice with 1, 10 and 25 ug of ELVIS-*neu*, ELVIS control and PBS by i.m. route. Evaluate humoral and cellular responses by flow cytometry, ELISA and CTL assays; 360 mice (months 1-9).

- Figure 2 (p. 262) and text page 263. We have immunized mice with increasing amounts of ELVIS-*neu* as shown in Figure 2 and the results were evaluated by flow cytometry. As shown, an antibody response resulted from the immunization and the response increased with increasing dose of ELVIS-*neu*. We did not evaluate results by ELISA since the flow cytometry was sufficient to conclude that a humoral immune response had been induced. As an alternative to CTL assays we performed an Interferon- γ (IFN- γ) release assay in which spleen cells from immunized mice were co-cultured for 5 days with P815 cells expressing *neu* or control P815 cells. The results clearly demonstrated IFN- γ only from spleen cells of mice vaccinated with ELVIS-*neu* and not from control mice or mice vaccinated with only ELVIS (Figure 6, p. 265). The IFN- γ release assay is widely used as an alternative to the CTL assay which has poor reproducibility and a very low signal to noise ratio.



- Immunize mice with single dosage of ELVIS-*neu*, ELVIS control and PBS using 1, 2, or 3 repeat i.m. injections. Evaluate humoral and cellular responses; 360 mice (month 3-12).
 - The result for the humoral immune response comparing one immunization and three immunization is shown in Figure 2a and Figure 2f (page 262) and text page 263.

2. The result for the antitumor cellular response is shown in Figure 4a-c (page 264) and text page 264-266.
- Determine if co-administration of cytokine encoding plasmids increases immune responses, 120 mice (months 13-34).
 1. The ELVIS2-*neu* plasmid has proven to be so powerful that I do not feel it is necessary to use a cytokine plasmid to attempt to increase the biological activity (see figure immediately below showing the effectiveness of ELVIS2-*neu* and ELVIS-*neu* on lung metastasis).
 - Determine whether liposomal-cytokine-peptide antigens can boost immune responses; 240 mice (months 13-34.)
 1. As above, the ELVIS2-*neu* plasmid has proven to be so powerful that I do not feel it is necessary to attempt to boost the immune response.
 - Challenge mice described above with the *neu*⁺ A2L2 cells and control 66.3 cells by injection in the mammary fatpad or i.v. Determine tumor growth rate, survival and level of pulmonary metastasis in vaccinated and control mice (months 6-30).
 1. The results for this experiment are shown in Figure 4 (page 264) and Figure 5 (page 265) and text pages 264-266.
 - Analyze results, prepare interim reports/publications (as appropriate).
 1. The enclosed publication (11) is our first report resulting from the research supported by this grant.

Task 2: To demonstrate that vaccination *after* tumor induction can reduce metastases and prolong survival (**therapeutic vaccination**) (months 18 - 36).

- Treat mice with different doses of A2L2 and 66.3 cells injected into mammary fatpad. Remove primary tumor and vaccinate at different times with ELVIS-*neu* and ELVIS. Score for incidence and extent of metastatic disease in different treatment groups; measure increased survival time in treated groups; 360 mice (month 18 - 36).
 1. We performed two therapeutic vaccinations in which a primary breast tumor of A2L2 cells was surgically removed on day 22 and the mice were vaccinated on days 25, 33 and 39 with ELVIS-*neu* (surgery model). The results from these experiments showed that therapeutic vaccination was not effective. The vaccine was not powerful enough to prolong the lives of the mice. We repeated this experiment twice using ELVIS2-*neu* rather than ELVIS-*neu*. Our conclusion is that neither plasmid, ELVIS-*neu* or ELVIS2-*neu* is sufficiently strong to rescue mice that have had a primary tumor surgically removed. We also tested both ELVIS-*neu* and ELVIS2-*neu* in a second therapeutic model in which the vaccine is given to mice with an actively growing tumor (race model) As with the surgery model, vaccination was ineffective at prolonging the life of the mice. We are now testing whether ELVIS-*neu* and ELVIS2-*neu* will be more potent in combination with chemotherapy. We are also currently testing if we

can use fewer cells in the race model in order to give the vaccination more of a chance to be effective before the tumor becomes overwhelming.

2. Figure 4b (page 264) clearly demonstrated that the immunity induced by vaccination with ELVIS-*neu* had no effect on the growth of 66.3 cells. Also, vaccination using ELVIS2-*neu* in mice challenged with 66.3 cells showed no effect. In a related experiment, mice that survived challenge with A2L2 following vaccinated with ELVIS-*neu* or ELVIS2-*neu* were challenged with 66.3 cells to determine if "cross priming" may have occurred to a "tumor antigen" present on 66.3 cells. All of the surviving mice died following challenge with 66.3 cells, indicating a lack of "cross priming" to the parental tumor.

KEY RESEARCH ACCOMPLISHMENTS:

- Vaccination of mice with increasing amounts of ELVIS-*neu* induces a proportionately greater level of humoral immunity.
- Vaccination of mice with ELVIS-*neu* results in the generation of *neu*-specific T cells in the spleen that release large amounts of IFN- γ in response to restimulation in vitro with *neu*-expressing cells.
- Vaccination with ELVIS-*neu* induces significant levels of anti-tumor immunity to breast cancer cells expressing *neu*. This is demonstrated by increased survival in vaccinated mice challenged in the mammary fat pad with a *neu*⁺ breast cancer cell line.
- The immunity to *neu* is antigen-specific and does not provide protection against a breast cancer cell line that does not express *neu*.
- Vaccination with ELVIS-*neu* also provides protection to challenge when tumor cells are injected i.v., thus demonstrating reduced lung metastasis as a result of vaccination.
- Neither ELVIS-*neu* nor ELVIS2-*neu* were sufficiently powerful to provide protection when mice were vaccinated after surgical removal of a primary breast tumor (surgery model). Also, neither ELVIS-*neu* nor ELVIS2-*neu* could protect mice when an active tumor was growing in the breast (race model).

REPORTABLE OUTCOMES:

1. One research report has been published (11).
2. This work has been presented at three scientific meetings:
 - 1) "DNA Vaccines", Keystone Symposia, Snowbird, UT, April, 1999 by Lawrence B. Lachman, Ph.D.
 - 2) American Association of Cancer Research, annual meeting in New Orleans, LA, April, 2000 by Janet Price, D.Phil.
 - 3) 3rd Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy, Walker's Cay, Bahamas, March, 2002.

3. The 66.3-*neo* and A2L2 cell lines were prepared before this application was funded. However, P815-*neu* cells were prepared for the IFN- γ release assay and these are valuable cells to have for future experimentation.
4. We have applied for a 2003 Department of Defense Breast Cancer Research Program Idea Award to perform combined vaccine therapy and chemotherapy in the therapeutic vaccine models.

CONCLUSIONS:

Our findings supported our hypothesis that vaccination with ELVIS-*neu* could induce cellular and humoral immunity able to increase survival and protect mice from challenge with a breast cancer cell line expressing *neu*. Unfortunately, this vaccine was not sufficiently powerful to protect mice from an actively growing tumor or from a surgically removed primary tumor that had already seeded metastases. Our work has clinical importance at this point. However, we believe that increased effectiveness of the vaccine by combination with chemotherapy would be much stronger justification for a clinical trial.

REFERENCES:

1. Fornier, M., P. Munster, and A. D. Seidman. 1999. Update on the management of advanced breast cancer. *Oncology* 13:647-658.
2. Disis, M. L., K. H. Grabstein, P. R. Sleath, and M. A. Cheever. 1999. Generation of immunity to the HER-2/*neu* oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. *Clin. Cancer Res.* 5:1289-1297.
3. Chattergoon, M., J. Boyer, and D. B. Weiner. 1997. Genetic immunization - a new era in vaccine and immune therapeutics. *FASEB Journal*. 11:753-763.
4. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Science* 292:69-74.
5. MacGregor, R. R., J. D. Boyer, K. E. Ugen, K. E. Lacy, S. J. Gluckman, M. L. Bagarazzi, M. A. Chattergoon, Y. Baine, T. J. Higgins, R. B. Ciccarelli, L. R. Coney, R. S. Ginsberg, and D. B. Weiner. 1998. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. *J Infect Dis.* 178:92-100.
6. Wang, R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, M. Sedegah, de, C. Taisne, J. A. Norman, and S. L. Hoffman. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. *Science* 282:476-480.
7. Roy, M. J., M. S. Wu, L. J. Barr, J. T. Fuller, L. G. Tussey, S. Speller, J. Culp, J. K. Burkholder, W. F. Swain, R. M. Dixon, G. Widera, R. Vessey, A. King, Ogg, G, A. Gallimore, J. R. Haynes, and D. H. Fuller. 2000. Induction of antigen-specific

- CD8+T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. *Vaccine* 19:764-778.
8. Hariharan, M. J., D. A. Driver, K. Townsend, D. Brumm, J. M. Polo, B. A. Belli, D. J. Catton, D. Hsu, D. Mittelstaedt, J. E. McCormack, L. Karavodin, T. W. Dubensky, Jr., S. M. Chang, and T. A. Banks. 1998. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. *J. Virol.* 72:950-958.
 9. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. *Cancer Res.* 61:3689-3697.
 10. Berd, D., H. C. Maguire, Jr., and M. J. Mastrangelo. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. *Cancer Res.* 46:2572-2577.
 11. Lachman, L. B., X.-M. Rao, R. H. Kremer, B. Ozpolat, G. Kiriakova, and J. E. Price. 2001. DNA vaccination against *neu* reduces breast cancer incidence and metastasis in mice. *Cancer Gene Ther.* 8:259-268.

APPENDIX

Reprint

Lachman, L. B., X.-M. Rao, R. H. Kremer, B. Ozpolat, G. Kiriakova, and J. E. Price. 2001. DNA vaccination against *neu* reduces breast cancer incidence and metastasis in mice. *Cancer Gene Ther.* 8:259-268.

DNA vaccination against *neu* reduces breast cancer incidence and metastasis in mice

Lawrence B. Lachman,¹ Xiao-Mei Rao,¹ Ronald H. Kremer,¹ Bulent Ozpolat,¹ Galina Kiriakova,² and Janet E. Price²

¹Department of Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030; and ²Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030.

The gene for HER2/*neu* is overexpressed in 30–40% of breast and ovarian cancers, and this overexpression correlates with increased metastasis and poor prognosis. The HER2/*neu* gene product, a transmembrane protein kinase member of the EGF receptor family, has significant potential as a tumor antigen for vaccination. We inserted the sequence for *neu* into a novel plasmid called ELVIS containing a Sindbis virus replicon that reproduces multiple copies of mRNA. Mice vaccinated one time intramuscularly demonstrated a strong antibody response against A2L2, a murine breast cancer cell line transfected to express *neu*. Vaccinated mice challenged in the mammary fatpad with A2L2 had reduced tumor incidence and reduced tumor mass compared to mice challenged with tumor cells lacking the *neu* insert. Intradermal vaccination was also protective and required 80% less plasmid for a similar level of protection. Vaccination reduced the incidence of lung metastasis from mammary fatpad tumors and reduced the number of lung metastases resulting from intravenous injection of A2L2 cells. Cytotoxic T lymphocytes cultures of immune spleen cells with P815-*neu* cells produced high levels of interferon- γ indicating an antigen-specific Th1-type immune response resulting from the vaccination. In a spontaneous breast tumor model using *neu* transgenic mice, vaccination with ELVIS-*neu* protected against development of spontaneous breast tumors. Our preclinical data indicate that therapeutic vaccination of patients with ELVIS-*neu* may reduce metastasis from HER2/*neu*-expressing breast and ovarian tumors. **Cancer Gene Therapy (2001) 8, 259–268**

Key words: Antitumor; *erbB-2*; gene vaccine.

One third of women with breast cancer who have no detectable lymph node involvement at the time of diagnosis will eventually develop metastatic disease. Despite advances in clinical management, once breast cancer has metastasized, the probability of a complete cure is greatly reduced.¹ Vaccination against breast cancer could be used to attack active disease and as an adjunct to surgery to control the growth of metastases.^{2,3} The presence of HER2/*neu*, a member of the tyrosine kinase receptor family, accelerates the growth and metastatic potential of breast cancer cells and reduces options for treatment. A vaccine that targets p185, the transmembrane protein encoded by HER2/*neu*, could have significant therapeutic and preventive application by controlling the growth and spread of the highly aggressive HER2/*neu*⁺ cells.² Indeed, Herceptin[®], a recently approved therapeutic monoclonal antibody, has p185 as its antigen target.⁴

Antitumor vaccines can be developed by immunizing with bacterial expression plasmids that encode the DNA sequence for *neu* or other tumor antigens.⁵ DNA vaccines have been

shown to induce a strong, lasting immune response that includes the generation of cytotoxic T lymphocytes (CTLs), the main mechanism for immunological control of tumor growth.⁶ We have vaccinated mice with ELVIS, a plasmid containing a Sindbis virus replicon which produces self-replicating RNA.⁷ ELVIS is the first part of a two-part vaccine strategy using viral particle replicons (VPRs) to boost the immune response induced by the initial plasmid vaccination.⁸ VPRs have been demonstrated to induce protective immunity against several infectious diseases such as Ebola hemorrhagic fever.⁹

We report here that vaccination of mice with ELVIS-*neu* resulted in an antibody response specific for *neu*-expressing A2L2 cells and the p185 gene product of *neu*. ELVIS-*neu*-vaccinated mice were protected from challenge with A2L2 breast tumor cells injected intravenously (i.v.) or directly into the mammary fatpad. CTL cultures of immune spleen cells from ELVIS-*neu*-vaccinated mice with the cell line P815-*neu* produced interferon- γ (INF- γ), but not interleukin-4 (IL-4), indicating antigen-specific induction of a Th1 immune response. Because the *neu* gene is of rat origin and could conceivably be recognized by mice as a foreign protein, we have also vaccinated MMTV-c-*neu* transgenic mice that spontaneously develop breast tumors.¹⁰ Vaccination with ELVIS-*neu*, but not ELVIS, protected the transgenic mice from developing spontaneous breast tumors,

Received November 2, 2000.

Address correspondence and reprint requests to Lawrence B. Lachman, PhD., Department of Bioimmunotherapy-60, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095. E-mail address: lachman@odin.mdacc.tmc.edu

indicating that ELVIS-*neu* induced protective immunity against *neu*-expressing breast tumors and thus broke tolerance to *neu*. We anticipate testing ELVIS-*neu* in a phase 1b clinical trial with the goal of breaking tolerance to HER2/*neu* by vaccinating with the gene for *neu* a related, but xenoantigenic, form of HER2/*neu*.

MATERIALS AND METHODS

Cell lines and culture conditions

The mouse mammary tumor cell line designated 66.3 was obtained from Dr. F. R. Miller (Karmanos Institute, Detroit, MI). This variant of a mammary tumor in a BALB/c mouse is tumorigenic and metastatic in syngeneic mice.¹¹ The cell line was free of *Mycoplasma* and of the following murine viruses: reovirus type 3, pneumonia virus, K virus, Theiler's encephalitis virus, Sendai virus, minute virus, mouse adenovirus, mouse hepatitis virus, lymphocytic choriomeningitis virus, ectromelia virus, and lactate dehydrogenase virus (assayed by M.A. Bioproducts, Walkersville, MD). The cells were maintained in monolayer culture in Eagle's minimum essential medium supplemented with 5% fetal calf serum, sodium pyruvate, nonessential amino acids, L-glutamine, and vitamins (GIBCO-BRL, Grand Island, NY) incubated in a humidified 5% CO₂-95% air incubator at 37°C. P815 mastocytoma cells were purchased from American Type Culture Collection (TIB-64, Manassas, VA) and cultured in suspension in same medium as the 66.3 cells described above.

Transfection to generate *neu*-expressing cells

Samples of 1×10^5 66.3 mammary tumor cells were plated in 35-mm culture dishes and 24 hours later, when 50–60% confluence had been achieved, the cells were transfected using Lipofectin (GIBCO-BRL). The culture medium was removed and a mixture of Lipofectin (20 μ L) and plasmid DNA in 2 mL of serum-free culture medium was prepared following the manufacturer's recommended procedure. The cells were incubated with either 5 μ g of pSV2-*neo* or 4.5 μ g of pSV2-*neu* plus 0.5 μ g of pSV2-*neo* (plasmids provided by Dr. M. -C. Hung, University of Texas M. D. Anderson Cancer Center). After 24-hour incubation, the plasmid-Lipofectin mixture was aspirated and replaced with culture medium containing 5% fetal bovine serum. After 2 days in culture, the cells were replated in 100-mm diameter plates, and 400 μ g/mL G418 was added to the medium. G418-resistant colonies were collected after 12–15 days growth, and the new clones expanded in culture. The transfected cells were maintained in culture in the presence of 400 μ g/mL G418, a concentration that killed all nontransfected 66.3 cells. P815 cells were transfected using the same plasmids. Aliquots of 2×10^5 cells were plated in 35-mm tissue culture plates and incubated for 24 hours with a mixture of plasmid DNA and Eugene (6 μ L; Boehringer Mannheim, Indianapolis, IN). The cells from each plate were recovered and divided between individual wells of 24-well culture plates in 1 mL of medium containing 600 μ g/mL G418. Wells with G418-resistant cells were identified after 10 days of culture, and these cells expanded in the culture.

Tumor cell injections

Tumor cells were harvested from subconfluent cultures by incubation with 0.25% trypsin and 0.02% EDTA solution for 1 minute at 37°C. The cells were dislodged from the culture flasks, washed in medium, centrifuged, and resuspended in phosphate-buffered saline (PBS). Female BALB/c mice were obtained from the Frederick Cancer Research Facility (Frederick, MD). To determine the experimental metastatic potential, tumor cell suspensions were injected into the lateral tail vein. Twenty-one days after i.v. injection, the mice were killed and the numbers of tumor colonies in the lungs recorded. To assess local tumor growth, cells were injected into the mammary fatpad. The mice were anesthetized by Metofane inhalation, the fur shaved over the lateral thorax, and a 5-mm skin incision made to reveal a mammary fatpad. The cells were injected in a volume of 0.1 mL into the fatty tissue, and the incision closed with a wound clip. Tumor growth was monitored by twice-weekly measurements using calipers.

Detection of p185 by immunoblotting

Protein extracts were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 7.5% acrylamide) and transferred to Hybond nitrocellulose filters (Amersham, Arlington Heights, IL). The filters were incubated for 16 hours at 4°C with 5% powdered milk in TBST (150 mM NaCl, 10 mM Tris-HCl, 1% Triton X-100, pH 8.0), washed in TBST, and then incubated for 1 hour at room temperature with a 1:1000 dilution of a polyclonal antibody to p185 (sc-284; Santa Cruz Biotechnology, Santa Cruz, CA) in TBST with 1% bovine serum albumin (BSA). The filters were washed in TBST, and then incubated for 1 hour with donkey antirabbit-horseradish peroxidase-conjugated antibody (Amersham) diluted 1:1000 in TBST with 1% BSA. The filters were washed and developed with ECL detection reagents and exposed to Hyperfilm (Amersham). Equal loading and transfer of proteins were confirmed by stripping the filters and reprobing with a 1:500 dilution of an antibody to actin (Sigma, St. Louis, MO) in TBST with 2.5% BSA.

Immunoprecipitation

Lysates of mammary tumor cells that were surface-labeled with NHS-LC-biotin (sulfo-succinimidyl-6-(biotinamido)-hexanoate; Pierce, Rockford, IL) were prepared as previously described.¹² Aliquots of 100 μ g of protein from 66.3 and A2L2 (p185-expressing) were precleared by incubation with mouse IgG and 30 μ L of protein A/protein G agarose (Oncogene Research Products, Cambridge, MA) for 1 hour. The precleared lysates were incubated for 16 hours with either normal mouse IgG, monoclonal antibody to p185 (Ab-3, Oncogene Research Products), IgG prepared using protein A agarose (BioRad, Hercules, CA) from sera collected from ELVIS-vaccinated mice, or IgG prepared from ELVIS-*neu*-vaccinated mice. Immune complexes were immunoprecipitated by 2-hour incubation at 4°C with protein A/protein G agarose (BioRad). The bound complexes were washed and separated on 7.5% SDS-PAGE gels under reducing conditions and transferred to nitrocellulose

filters. Biotin-labeled proteins were detected by incubating the filters with horseradish peroxidase-linked streptavidin (Pierce, St. Louis, MO) and ECL detection reagents (Amersham, Piscataway, NJ).

Plasmids used for vaccination

The ELVIS plasmid was obtained from John Polo (Chiron Technologies, San Diego, CA) and has been previously described in detail.¹³ Rat *neu* sequence was excised from pSV2-*neu* (described above) and inserted into ELVIS by standard techniques. The correct insertion of the complete gene was confirmed by sequence analysis.

Vaccination of mice

Intramuscular (i.m.) injections of 0.1 mL were administered to the quadriceps with a 24-gauge needle. Intradermal (i.d.) injections of 0.20 mL were administered on the shaved back also using a 24-gauge needle. The i.m. injections contained 100 μ g of plasmid DNA and were formulated with 0.25% bupivacaine (Sigma). The i.d. injections were similarly formulated, but contained only 20 μ g of DNA. At indicated times, blood was collected from the tail vein and serum separated by centrifugation after incubation at 37°C for 1 hour.

Flow cytometry

Either A2L2 or 66.3 cells were mixed with immune serum diluted 1:100 in PBS and incubated for 1 hour at 37°C. Fluorescein isothiocyanate (FITC)-labeled goat antimouse IgG (Pharmingen, San Diego, CA) diluted 1:1000 in PBS was added to the cell suspension, and the mixture incubated for 1 hour at 37°C. The cells were washed by centrifugation three times in PBS and then analyzed by flow cytometry using an EPICS Profile Analyzer (Coulter, Hialeah, FL).

CTL cultures and cytokine release assays

Spleens from mice vaccinated one time i.m. with either 100 μ g of ELVIS-*neu* or 100 μ g of ELVIS were harvested 9 weeks postvaccination. The spleens were homogenized by forcing through a stainless steel mesh using a syringe plunger into a Petri dish containing 10 mL of RS10 media

(RPMI 1640, 10% heat-inactivated fetal calf serum, 1% nonessential amino acids, 100 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL penicillin, 100 μ g/mL streptomycin, 50 μ M 2-mercaptoethanol). Debris was removed from the cell suspension by filtering through nylon mesh into a 10-mL centrifuge tube. The cell suspension was centrifuged for 10 minutes at 700 $\times$ g and the pellet was resuspended in 5 mL of AKC solution (0.15 M NH₄Cl, 1.0 mM KHCO₃, 0.1 mM NaEDTA, pH 7.4) for 5 minutes with gentle rocking to lyse the red blood cells. An additional 5 mL of RS10 media was added to the cell suspension and the cells were washed one time with RS10 media. P815-*neu* and P815 parental cells were γ -irradiated (37 Gy for 1.25 minutes) and 2×10^7 spleen cells were cultured with either 1×10^7 irradiated P815-*neu* or P815 cells in 10 mL of R10S in six-well plates for 5 days at 37°C. Control cultures of only spleen and only P815 or P815-*neu* cells were cultured under identical conditions. Supernatants from the mixed leukocyte-tumor and the control cultures were collected following centrifugation and assayed for the presence of IL-4 and INF- γ using the mouse IL-4 and mouse INF- γ OptEIA sets from Pharmingen.

Vaccination of MMTV-c-*neu* transgenic mice

Female MMTV-c-*neu* transgenic mice¹⁴ were purchased from Charles Rivers Laboratories (Wilmington, MA). Groups of 10 seven-week-old mice were injected i.m. with 100 μ g of either ELVIS-*neu* or control ELVIS plasmid DNA, prepared as described above. Each mouse received three injections at 2-week intervals. The date of detection of palpable mammary tumors on each mouse was recorded.

RESULTS

Transfection of 66.3 mammary tumor cells with pSV2-*neu*

The 66.3 mammary tumor cells did not express elevated levels of p185 (Fig 1). To create a tumor target with high expression of this potential tumor antigen, we transfected 66.3 cells with pSV2-*neu* and pSV2-*neo*. After cell lines were established in culture, the cells were injected i.v. into Balb/c mice and individual lung metastases were established as continuous cell lines. Protein lysates prepared from these




Figure 1. Immunoblot analysis of p185 expression in 66.3 mammary tumor cells transfected with pSV2-*neu*. A protein lysate of the human ovarian cancer cell line SKOV3ip1 was used as a positive control, expressing abundant 185-kDa protein. The 66.3 and 66.3-*neo* cells expressed minimal amounts of p185. The 10 lysates prepared from lung metastases in mice injected with 66.3 cells transfected with pSV2-*neu* showed variable levels of p185 expression. The cell line designated A2L2 was used for the subsequent tumor challenge experiments.



in vivo-selected clones were analyzed by immunoblotting to detect p185 expression. Several clones showed significantly more p185 expression than the 66.3 parental cells or the control transfected cells (66.3-*neo*) (Fig 1). When the *neu*-transfected cells were injected into BALB/c mice, either i.v. or into the mammary fatpad, the rates of tumor take, tumor growth, and numbers of lung metastases that developed were indistinguishable from the parental 66.3 mammary tumor cells or the control 66.3-*neo* cells (data not shown). Thus, transfection with pSV2-*neu* did not alter the tumorigenic or metastatic potential of these cells.

Not all of the lung metastasis-derived lines retained high expression of p185 (Fig 1), suggesting that the injected cells were a heterogeneous mixture of p185-positive and -negative cells, or alternatively, that in the absence of G418 selection pressure *in vivo*, the inserted *neu* gene was eliminated from the mammary tumor cells. Loss of p185 and/or neomycin resistance was noted in 24–36% of the metastasis-derived clones. The A2L2 clone was selected for the tumor challenge experiments because it retained a high level of p185 expression (Fig 1). The level of p185 expression by the A2L2 cell line has remained consistently




Figure 2. Flow cytometric analysis of A2L2 cells with pooled antisera resulting from vaccination of mice with increasing amounts of ELVIS-*neu* or ELVIS. Mice were vaccinated one time i.m. with 1, 10, 25, or 50 µg of ELVIS-*neu* (panels a–d). Control mice were vaccinated once with 50 µg of ELVIS (panel e). Panel f shows the increase in antibody response resulting from vaccination of mice three times with 100 µg of ELVIS-*neu*. Panel g shows the lack of immunofluorescence with A2L2 cells in the absence of immune sera, and panel h shows the lack of immunofluorescence when the antisera in panel A were tested using 66.3-*neo* cells.

high relative to the control 66.3-*neo* cells for more than 1.5 years as measured by immunoblotting and flow cytometry. Immunohistochemistry of lung metastases in mice injected with A2L2 cells revealed p185 expression in the tumor cells (data not shown). Thus, the tumor challenge target cell line, A2L2, was shown to express p185 *in vitro* and *in vivo* and to be tumorigenic and metastatic in syngeneic mice.

Induction of antibody to A2L2 cells by vaccination with ELVIS-*neu*

Groups of five Balb/c mice were vaccinated one time i.m. with increasing doses of ELVIS-*neu* (1–50 μ g), and 2 weeks later, the presence of IgG in the pooled sera was evaluated by flow cytometry using A2L2 cells. As shown in Figure 2a–d, increasing the vaccination dose of ELVIS-*neu* increased immunofluorescence. Sera obtained by vaccination with a single dose of the backbone ELVIS plasmid lacking the *neu* insert did not result in positive staining of the A2L2 cells (Fig 2e). Immune sera obtained from mice vaccinated three times i.m. at 2-week intervals had the highest level of immunofluorescence (Fig 2f). There was no staining in the absence of immune serum (Fig 2g), and the pooled antisera from panel A did not stain 66.3-*neo* cells (Fig 2h), demonstrating that the immunofluorescence was specific for A2L2 cells and did not detect an epitope also expressed on 66.3-*neo* cells. These results demonstrated that ELVIS-*neu* was able to induce a humoral immune response specific for an expressed antigen of *neu*.

Immunoprecipitation of p185 from A2L2 cells with immune sera

When the protein product of *neu*, p185, was expressed in the cytosol of A2L2 cells, part of the intact molecule could be

directed to the plasma membrane for presentation as a receptor and another part processed for presentation on Class I molecules. We performed immunoprecipitation on surface-radiolabeled A2L2 and 66.3 cells with a commercial monoclonal Ab to p185 and with immune sera described above. As shown in Figure 3, the monoclonal *Neu*-Ab3 precipitated p185 from A2L2 cells, whereas control IgG did not. Purified IgG from mice injected three times with 100 μ g of ELVIS-*neu* also immunoprecipitated a band at 185 kDa from the A2L2 cells, but not from the 66.3-*neo* cells. Immune sera from mice injected three times with 100 μ g of the backbone plasmid ELVIS did not precipitate an equivalent band in either 66.3-*neo* or A2L2 cells. These results demonstrate expression of the *neu* transgene in A2L2 cells with transport of some of the translated p185 proteins to the plasma membrane. In addition, the immunoprecipitation of p185 with the antisera resulting from vaccination with ELVIS-*neu* demonstrated an immune response to p185, the transgene product.

Protection from tumor induction following i.m. vaccination with ELVIS-*neu*

Groups of five mice were vaccinated one time i.m. with 100 μ g of either ELVIS-*neu*, ELVIS, or PBS and challenged 14 days later by injection of 1.0×10^4 A2L2 or 66.3-*neo* cells into the mammary fatpad. The mice were monitored daily for palpable tumors and the tumors were measured with calipers when sufficiently large. As shown in Figure 4a, when challenged with A2L2 cells, the mice vaccinated with a single injection of 100 μ g of ELVIS-*neu* had a 60% tumor incidence compared to 100% for mice injected with ELVIS and 80% for mice injected with PBS. In contrast, the same vaccinations offered no protection from tumor incidence when mice were challenged with 66.3-*neo* (Fig 4b). There was no significant difference in the size of tumors in any




Figure 3. Immunoprecipitation of a 185-kDa protein from A2L2 lysates with IgG from ELVIS-*neu*-vaccinated mice. The products of immunoprecipitation reactions using lysates of biotin-labeled tumor cells and IgG from vaccinated mice (ELVIS or ELVIS-*neu*), control mouse IgG, or monoclonal antibody to p185 (*Neu*-Ab3) were separated on a 7.5% SDS-polyacrylamide gel and transferred to nitrocellulose. The biotin-labeled bands were detected following incubation with HRP-streptavidin and ECL reagents. A 185-kDa band was precipitated by *Neu*-Ab3 and IgG from the sera of ELVIS-*neu*-vaccinated mice from lysates of A2L2 cells, and not from lysates of the 66.3-*neo* cells.




Figure 4. Tumor protection from vaccination with ELVIS-*neu*. **a:** Time course of tumor incidence in mice vaccinated with ELVIS (■), ELVIS-*neu* (▲), or PBS (●). Groups of 10 mice received 100 μ g of DNA or 0.1 mL PBS injected i.m. in the hind leg. Two weeks later, the mice were challenged with injection of A2L2 cells in the mammary fatpad. The mice were examined daily and the incidence of palpable tumors (≥ 1 mm) was recorded. The incidence of tumor in the ELVIS-*neu*-vaccinated mice was reduced compared with the ELVIS-vaccinated mice, but the difference was not significant ($P=.087$, Fisher's exact test). **b:** Mice were vaccinated as in panel a and challenged with 66.3-*neo* cells. The vaccination with ELVIS or ELVIS-*neu* gave no protection against the mammary tumor cells lacking high expression of p185. **c:** Groups of 15 mice were injected three times at 2-week intervals with ELVIS (■), ELVIS-*neu* (▲), or PBS (●). Two weeks after the final vaccination, the mice were challenged by injection of A2L2 cells in the mammary fatpad, and tumor incidence recorded. The incidence of tumors in the ELVIS-*neu* group was significantly reduced compared with the ELVIS-vaccinated group ($P=.0092$, Fisher's exact test). **d:** Groups of 10 mice were vaccinated i.d. with 20 μ g of ELVIS or ELVIS-*neu* DNA, three times at 2-week intervals, and then challenged with injection of A2L2 cells into the mammary fatpad. The tumor incidence was not significantly lower in the ELVIS-*neu* group, but the tumor weight (mice were killed 35 days after injection) was significantly lower in this group compared with weights of tumors in the ELVIS-vaccinated mice ($P=.02$, unpaired *t* test).

group. These results indicated that vaccination with ELVIS-*neu* resulted in some protection from tumor challenge with A2L2, but no protection against 66.3-*neo* cells.

Based on these results, a subsequent experiment was performed using groups of 10 mice each, and the vaccination regimen was increased to three i.m. injections of 100 μ g given at 14-day intervals. The mice were challenged as above, with 1.0×10^4 A2L2 cells 14 days after the third vaccination. As shown in Figure 4c, only 20% of mice vaccinated with ELVIS-*neu* developed tumors compared to 80% in mice vaccinated with ELVIS and 100% for PBS. This significant difference ($P<.0092$) in tumor incidence clearly demonstrated that vaccination with

an expression plasmid containing the cDNA for *neu* was protective against challenge with a *neu*-transfected tumor compared to challenge with the parental tumor not expressing *neu*. ELVIS-*neo* injection provided 20% protection compared to PBS, a result commonly referred to as a plasmid effect.

Protection from tumor induction following i.d. vaccination with ELVIS-*neu*

To determine if we could verify the protective effect of the ELVIS-*neu* vaccine using a route other than i.m., we vaccinated groups of 10 mice i.d. with ELVIS-*neu* and

Table 1. Comparison of i.m. and i.d. Injection Route*

Vaccine group	Injection route	Tumor incidence	Mean tumor weight (g) $\pm$ SEM	Metastasis incidence	Median number of metastases (range)
ELVIS- <i>neu</i>	i.m.	9/10	0.62 $\pm$ 0.15†	4/10	0 (0–5)
ELVIS	i.m.	10/10	1.10 $\pm$ 0.12	8/10	3 (0–6)
ELVIS- <i>neu</i>	i.d.	8/10	0.44 $\pm$ 0.14‡	4/10	0 (0–4)
ELVIS	i.m.	10/10	1.40 $\pm$ 0.34	7/10	1.5 (0–3)

*Groups of 10 mice were vaccinated three times at 2-week intervals with 20 μ g of either ELVIS-*neu* or ELVIS. Two weeks following the final vaccination, 1×10^4 A2L2 cells were injected into the mammary fatpad and 36 days later, the mice were killed.

† $P = .0365$ ELVIS-*neu* i.m. versus ELVIS i.m.

‡ $P = .0193$ ELVIS-*neu* i.d. versus ELVIS i.d.

ELVIS. Because it has been frequently demonstrated that i.d. vaccination requires lower doses of plasmid than i.m. vaccination, we reduced the dose to 20 μ g of plasmid and vaccinated three times, compared to the previous i.m. experiment using 100 μ g of plasmid and three vaccinations. As shown in Figure 4d, the tumor incidence for A2L2 was 60% for ELVIS-*neu*-vaccinated mice compared to 100% for mice vaccinated with ELVIS. When the mice were sacrificed 35 days after tumor challenge, the mean tumor weight for the six mice that developed tumors following ELVIS-*neu* injection was significantly lower than the mean tumor mass for the 10 mice vaccinated with ELVIS. Thus, vaccination with ELVIS-*neu* reduced the incidence of tumor induction and lowered the mass of tumors that did develop. Similar results were obtained when this exact experiment was repeated using three, rather than one, vaccination (Table 1). In addition to a decrease in the mean weight of the tumors

that did develop, 0.44 g for ELVIS-*neu*-vaccinated versus 1.40 g for ELVIS-vaccinated, the incidence of metastasis was lower in the ELVIS-*neu*-vaccinated group. Serum samples from the vaccinated mice were analyzed by flow cytometry exactly as described in Figure 2. Mice vaccinated with ELVIS-*neu* by either i.m. or i.d. had an equivalent antibody response to A2L2 cells that was not present in mice vaccinated with ELVIS (data not shown because identical to Figure 2).

Protection from experimental metastasis following i.m. vaccination with ELVIS-*neu*

In addition to vaccination's inhibition of primary-site tumor induction, we wanted to determine if vaccination could reduce metastasis to the lungs. The A2L2 cells can metastasize from the mammary fatpad tumors, but because the time period for this to occur varied between experiments, there was no way to determine the level of metastasis prior to sacrificing the mice. An alternative model, referred to as experimental metastasis, is to inject A2L2 cells i.v. and measure the number of lung metastases at a time previously determined for A2L2 cells. Groups of 10 mice vaccinated three times i.m. with 100 μ g of ELVIS, ELVIS-*neu*, or PBS were injected i.v. with 1×10^4 A2L2 cells 14 days following the last vaccination. On day 21, the mice were sacrificed and the lung metastases counted by eye. As shown in Figure 5, 3




Figure 5. ELVIS-*neu* protection against experimental metastasis of A2L2 cells. Groups of 10 mice were vaccinated three times with 100 μ g of ELVIS or ELVIS-*neu* DNA, or with 0.1 mL of PBS by i.m. injection at 2-week intervals. Fourteen days after the final vaccination, the mice were injected i.v. with 1×10^4 A2L2 cells. The mice were killed 21 days later, and the lung metastases counted. There were significantly fewer metastases in the ELVIS-*neu*-vaccinated mice ($P = .031$), but not in ELVIS-vaccinated mice ($P = .49$), compared with the PBS-injected mice (unpaired *t* test).




Figure 6. CTL cultures of immune spleen and P815-*neu* cells. Spleens from mice vaccinated one time i.m. with either 100 μ g of ELVIS-*neu* were co-cultured for 5 days with irradiated P815-*neu* or P815 cells. The amount of INF- γ and IL-4 in the culture supernatants is shown on the ordinate.



of 10 mice vaccinated with ELVIS-*neu* did not have lung metastases compared to 1 of 10 for PBS-injected mice and 0 of 10 for ELVIS-injected mice. In addition, the number of metastases in the ELVIS-*neu*-vaccinated mice was significantly lower than in the ELVIS-vaccinated mice. In a repeat of this experiment we injected 2.5×10^4 A2L2 cells, resulting in greater lung tumor burden, but even so there were significantly fewer metastases in the ELVIS-*neu*-vaccinated mice.

CTL cultures and cytokine release assays

Spleen cells from mice vaccinated once i.m. 9 weeks earlier with either 100 μ g of ELVIS-*neu* or ELVIS were cultured with irradiated P815-*neu* or P815 cells for 5 days and the amount of INF- γ and IL-4 in the supernatant was determined.^{7,15,16} As shown in Figure 6, immune spleen cells co-cultured with P815-*neu* cell released an average of 1700 pg of INF- γ , whereas the same spleen cells co-cultured with P815 cells not expressing *neu* released background levels of INF- γ . There was negligible IL-4 production from either co-culture condition. These results clearly demonstrate that vaccination has induced a Th1 response and that the response is antigen-specific for p185, the gene product of *neu*, because co-culture with P815 cells did not stimulate the release of INF- γ .

Vaccination of MMTV-*c-neu* transgenic mice

Because the *neu* gene is of rat origin, the possibility exists that mice could recognize the gene product as a xenoantigen. Fortunately, a rat *neu* transgenic mouse is available in which *neu* gene expression is under the control of an MMTV promoter and *neu*⁺ breast tumors spontaneously develop at about 25 weeks of age.¹⁴ Two groups of ten FVB/N mice 8 weeks of age were vaccinated three times at 2-week intervals with 100 μ g of ELVIS-*neu* or ELVIS. The mice received no further treatment. As shown in Figure 7, at 150 days after the first vaccination, palpable breast tumors developed in 9 of 10 mice vaccinated with ELVIS and only 6 of 10 mice vaccinated with ELVIS-*neu*. The onset of first breast tumors was delayed by approximately 40 days in the ELVIS-*neu*-vaccinated mice.




Figure 7. FVB/N *neu* transgenic mice vaccinated with ELVIS-*neu* or ELVIS. Eight-week-old mice were vaccinated three times at 2-week intervals with 100 μ g of either ELVIS-*neu* or ELVIS. The mice were monitored for the spontaneous development of breast tumors.

DISCUSSION

Nucleic acid immunization was introduced by Wolff et al,¹⁷ who showed that injection of plasmid DNA into skeletal muscle led to protein expression. Subsequent studies showed that plasmid DNA injection could evoke long-lasting cellular and humoral responses against the products of the injected genes.¹⁸ Chen et al¹⁹ demonstrated that vaccination of mice with plasmids expressing either full-length *neu* or its extracellular domain induced substantial protective immunity against challenge with a *neu*-expressing mouse mammary tumor. Amici et al,²⁰ using *neu* transgenic mice, demonstrated that genetic vaccination with *neu* reduced the outgrowth of mammary tumors. In this report, we are also vaccinating with *neu*; however, we are using an expression plasmid containing a Sindbis virus replicon.⁸ The expression plasmid ELVIS utilizes a self-replicating virus vector RNA for gene expression. ELVIS is the first part of a two-part vaccine strategy. In the first part, ELVIS is used to induce a primary immune response and in the second part, VPRs are used to boost the immune response.⁸ VPRs have been demonstrated to induce protective immunity against several infectious diseases.⁹

ELVIS, a strong expression vector, is reported to induce antibody and CTL to the encoded protein when injected i.m. into mice at a 100- to 1000-fold lower doses than would be required for a comparable response using constructs of conventional expression vectors.¹³ We found that a single i.m. injection with 1 μ g of ELVIS-*neu* induced an antibody response to A2L2 cells expressing p185, a 50- μ g injection increased the Ab response, and three 100- μ g injections increased it still further (Fig 2). The humoral immune response resulting from ELVIS-*neu* vaccination appeared to be specific for cells transfected with *neu* because there was no reaction with 66.3 cells that do not express p185, the protein product of the *neu* gene (Fig 2). In addition, immunoprecipitation using purified IgG from mice vaccinated with ELVIS-*neu* demonstrated specificity for p185 (Fig 3).

A single i.m. vaccination with 100 μ g of ELVIS-*neu* protected mice from developing tumors when challenged in the mammary fatpad with the A2L2, and this effect was specific for the A2L2 cells because it did not occur in 66.3-*neo* cells (Fig 4). Increasing the number of vaccinations with ELVIS-*neu* from one to three greatly improved this result with only 2 of 10 mice developing tumor compared to 8 of 10 vaccinated with ELVIS (Fig 4). The effective route of vaccination was not restricted to i.m., because i.d. vaccination with ELVIS-*neu* reduced tumor incidence in 6 of 10 mice (Fig 4) and 8 of 10 (Table 1) compared with 10 of 10 in mice given ELVIS vaccination. Furthermore, i.d. injection required only 20 μ g of plasmid for each injection compared with the 100 μ g required for i.m. vaccination. We did not test fewer than three i.d. injections. An interesting effect from i.d. injections that we did not observe with i.m. injections was reduced tumor mass in mice vaccinated with ELVIS-*neu* compared to ELVIS (Fig 4 and Table 1). Thus, even though a tumor developed, it is possible that the growth may be retarded by an immune mechanism.

It has been reported that ELVIS can induce CTL at very low doses¹³ and to confirm this, we prepared CTL cultures of immune spleen cells and P815 cells transfected with *neu*.^{7,15} As shown in Figure 6, spleen cells from mice vaccinated with ELVIS-*neu* and co-cultured with P815-*neu* cells produced high levels of INF- γ and negligible IL-4. Cultures of immune spleen cells with control P815 cells lacking *neu* did not secrete either cytokine. Other control cultures of ELVIS-vaccinated spleen cells with either P815 or P815-*neu* also produced negligible levels of INF- γ and IL-4. These results confirm that vaccination with ELVIS-*neu* is inducing a Th1 response that is specific for gene product of *neu* and indicates that T-cell immunity is the most likely explanation for reduced tumor incidence and reduced tumor mass in ELVIS-*neu*-vaccinated mice.

Vaccination with ELVIS-*neu* protected 3 of 10 mice from developing lung metastases following i.v. injection of A2L2 cells and reduced the mean number of lung metastases that did develop compared to mice injected with ELVIS (Fig 5). The i.v. injection of tumor cells is an experimental model of tumor metastasis in which tumor cells arrest and grow predominantly in the lungs, which is the first capillary bed they encounter. Reduction of lung metastases in this model by vaccination with ELVIS-*neu* indicates that metastasis from a primary breast tumor can be reduced. It is possible that a more robust immune response induced by prime-boost vaccination with the combination of ELVIS-*neu* followed by VPR-*neu* could reduce or even eliminate metastasis from a primary tumor. Vaccination with ELVIS-*neu* was also able to reduce spontaneous metastasis resulting from a tumor in the mammary fatpad. As shown in Table 1, both i.m. and i.d. vaccinations with ELVIS-*neu* resulted in lower incidence of lung metastasis from a primary tumor. Leitner et al⁷ have also shown reduced metastasis from a primary tumor following vaccination with a replicon containing DNA vaccine.

The *neu* gene that we have used for transfection of the 66.3 and P815 cells and for the creation of ELVIS-*neu* is of rat origin. Thus, a possibility exists that mice vaccinated with *neu* could be responding to p185 as a xenoantigen, even though the primary sequence of *neu* is highly conserved between rat and mice. A way to eliminate the xenoantigen possibility is to use *neu* transgenic mice that are tolerant to *neu*. In FVB/N mice, expression of the *neu* transgene is regulated by the mouse mammary tumor virus promoter and the mice spontaneously develop breast tumors at about 25 weeks of age.¹⁴ The *neu* transgene used to develop this strain of mice is "activated" *neu* which contains a single amino acid substitution.¹⁴ Using FVB/N mice, we found that vaccination with ELVIS-*neu* significantly retarded the development of spontaneous breast tumors (Fig 7). In addition, at 150 days postvaccination, 4 of 10 mice vaccinated with ELVIS-*neu* had not developed tumors compared with 1 of 10 mice vaccinated with ELVIS. Therefore, vaccination with ELVIS-*neu* both delayed tumor development and, in some mice, eliminated tumor development. Thus, tolerance to *neu* is not absolute in FVB/N mice and can be broken by vaccination with ELVIS-*neu*.

Once we have established the prime-boost protocol for ELVIS-*neu* and VPR-*neu*, we plan to test therapeutic

vaccination. In this model, primary A2L2 tumors in the mammary fat will be surgically removed after metastases have already been seeded in distant organs and then the mice will be vaccinated. This model of therapeutic vaccination is more representative of the clinical situation in which patients with resected *neu*-positive tumors relapse due to distant metastasis.¹ Metastasis is the major cause of breast cancer deaths.¹ Surgery can cure breast cancer, but not if metastasis has occurred before detection and local tumor therapy. A vaccine targeting HER2/*neu* could potentially target established metastases, or prevent new metastases from disseminating from other lesions. Although DNA vaccines utilizing ELVIS have not yet been tested in clinical trials, we believe that the current findings justify further research and development of this potent new strategy to target metastatic breast cancer. We anticipate vaccinating patients with ELVIS-*neu* containing the gene for rat *neu* based on our findings shown in this report that the gene product, p185, from a highly conserved but foreign species can be used successfully for vaccination and will break tolerance to the native gene product. We are hopeful that the immunity which develops in vaccinated patients will be directed at the rapidly dividing breast cancer cells that greatly overexpress p185 and not to normal cells that express very low levels of the same protein.

ACKNOWLEDGMENTS

We thank Walter Pagel, Department of Scientific Publications, for careful review of this manuscript and Craig A. Mullen, Department of Pediatrics, for assistance with the CTL cultures. This research was supported by the US Army Medical Research and Materiel Command, Department of Defense Breast Cancer Research Program, BC980071 and the W. M. Keck Center for Cancer Gene Therapy; The Breast Cancer Research Program; The Kleberg Fund for New and Innovative Research; and the Physicians Referral Service of The University of Texas M. D. Anderson Cancer Center and CA16672 from the National Cancer Institute.

REFERENCES

1. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. *Oncology*. 1999;13:647-658.
2. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/*neu* oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. *Clin Cancer Res*. 1999;5:1289-1297.
3. Ross JS, Fletcher JA. The HER-2/*neu* oncogene: prognostic factor, predictive factor and target for therapy. *Semin Cancer Biol*. 1999;9:125-138.
4. Weiner LM. An overview of monoclonal antibody therapy of cancer. *Semin Oncol*. 1999;26:41-50.
5. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of cancer. *Semin Oncol*. 1996;23:135-147.
6. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. *Annu Rev Immunol*. 2000;18:927-974.

7. Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. *Cancer Res.* 2000;60:51–55.
8. Dubensky TW Jr, Polo JM, Liu MA. Live virus vaccines: something old, something new, something borrowed. *Nat Med.* 1998;4:1357–1358.
9. Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. *Vaccine.* 2000;19:142–153.
10. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci USA.* 1992;89:10578–10582.
11. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. *Invasion Metastasis.* 1983;3:22–31.
12. Mukhopadhyay R, Theriault RL, Price JE. Increased levels of 6 integrins are associated with the malignant phenotype of human breast cancer cells. *Clin Exp Metastasis.* 1999;17:325–332.
13. Hariharan MJ, Driver DA, Townsend K, et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. *J Virol.* 1998;72:950–958.
14. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. *Cell.* 1988;54:105–115.
15. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. *J Exp Med.* 2000;191:1699–1708.
16. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J Exp Med.* 1999;190:355–366.
17. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle *in vivo*. *Science.* 1990;247:1465–1468.
18. Chattergoon M, Boyer J, Weiner DB. Genetic immunization — a new era in vaccine and immune therapeutics. *FASEB J.* 1997;11:753–763.
19. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated *neu* induce protective immunity against *neu*-expressing mammary tumors. *Cancer Res.* 1998;58:1965–1971.
20. Amici A, Smorlesi A, Noce G, et al. DNA vaccination with full-length or truncated *neu* induces protective immunity against the development of spontaneous mammary tumors in HER-2/*neu* transgenic mice. *Gene Ther.* 2000;7:703–706.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MD 21702-5012

REPLY TO
ATTENTION OF

MCMR-RMI-S (70-1y)

15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB266022	ADB265793
ADB260153	ADB281613
ADB272842	ADB284934
ADB283918	ADB263442
ADB282576	ADB284977
ADB282300	ADB263437
ADB285053	ADB265310
ADB262444	ADB281573
ADB282296	ADB250216
ADB258969	ADB258699
ADB269117	ADB274387
ADB283887	ADB285530
ADB263560	
ADB262487	
ADB277417	
ADB285857	
ADB270847	
ADB283780	
ADB262079	
ADB279651	
ADB253401	
ADB264625	
ADB279639	
ADB263763	
ADB283958	
ADB262379	
ADB283894	
ADB283063	
ADB261795	
ADB263454	
ADB281633	
ADB283877	
ADB284034	
ADB283924	
ADB284320	
ADB284135	
ADB259954	
ADB258194	
ADB266157	
ADB279641	
ADB244802	
ADB257340	
ADB244688	
ADB283789	
ADB258856	
ADB270749	
ADB258933	